GigaGen
South San Francisco
About GigaGen
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $38.4M
- Funding stage: M&A
- Last round: Private Equity (Jul 2017)
- Website: gigagen.com
- Phone: (415)978-2101
Industries & Categories
Biotechnology, Genetics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/gigagen-100857 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.